The FDA is pushing for a "BlackBox" warning on the diabetes drug Avandia. The drug came under pressure in May when a U.S. analysis linked Avandia to a 43% higher risk of heart attack.
An advisory panel to the FDA recommended that Avandia stay on the market, but said it should have increase warnings.
Avandia posted global sales of $3.24 billion last year making it the company's second best seller. But sales have plummeted since the May study linking it to increased risk of heart attack.
successful with herbal, vitamins and minerals